ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection

Abstract

Cardiometabolic disease, especially hypertension, is a common risk factor for mortality among individuals with SARS-CoV-2 disease (COVID-19). The role of hypertension and vascular disease in COVID-19 has raised considerable debate around how to best manage anti-hypertensive therapy to alter disease trajectory. Given the role of the ACE2 receptor in SARS-CoV-2 viral entry6, angiotensin system modulation by ACE inhibitors (ACE-I) or angiotensin-II receptor blockers (ARBs) in clinical management have taken center stage in this controversy.